Evidence map›Paper›PMID 42084636›Full record

ReviewArchives of microbiology2026

mRNA vaccine development for tuberculosis: antigen design, immune mechanisms, and translational challenges.

Qamar Abuhassan, Mohamed Abu Shuheil, Narinderjit Singh Sawaran Singh, Praharshkumar B Raj, Subbulakshmi Ganesan, Subhashree Ray, Harvinder Singh Sohal, Omayma Salim Waleed, Shakhnozakhon Muminova, Mutabar Latipova and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Qamar AbuhassanDepartment of Pharmaceutics and Pharmaceutical Technology, School of Pharmacy, University of Jordan, Amman, 11942, Jordan. qamarabuhassan9@gmail.com.
Mohamed Abu ShuheilFaculty of Allied Medical Sciences, Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan.
Narinderjit Singh Sawaran SinghFaculty of Data Science and Information Technology, INTI International University, Persiaran Perdana BBN, Putra Nilai, 71800, Nilai, Malaysia. narinderjits.sawaran@newinti.edu.my.
Praharshkumar B RajDepartment of Chemistry, Faculty of Science, Gokul Global University, Sidhpur, Gujarat, India.
Subbulakshmi GanesanDepartment of Chemistry and Biochemistry, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India.
Subhashree RayDepartment of Biochemistry, IMS and SUM Hospital, Siksha 'O' Anusandhan (Deemed to be University), Bhubaneswar, Odisha, 751003, India.
Harvinder Singh SohalDepartment of Chemistry, University Institute of Sciences, Chandigarh University, Mohali, Punjab, India.
Omayma Salim WaleedDepartment of Anesthesia Techniques, Health and Medical Techniques College, Alnoor University, Mosul, Iraq.
Shakhnozakhon MuminovaDenau Institute of Entrepreneurship and Pedagogy, Denau 190500, Uzbekistan.
Mutabar LatipovaNational Research University TIIAME, Kori Niyoziy 39, 100000, Tashkent, Uzbekistan.
Dilfuza BegmatovaNational University of Uzbekistan, 100174, Tashkent, Uzbekistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The persistent global burden of tuberculosis (TB) and the context-dependent efficacy of the Bacillus Calmette-Guérin (BCG) vaccine necessitate the development of innovative prophylactic strategies. mRNA vaccine platforms have emerged as a transformative toolkit, offering unprecedented versatility in antigen design and manufacturing scalability. This inclusive innovation review synthesizes the molecular engineering and immunological mechanisms of mRNA TB vaccines, evaluating their capacity to address the unique challenges posed by the intracellular lifestyle of Mycobacterium tuberculosis (Mtb). mRNA platforms realistically offer superior endogenous antigen production for CD8⁺ T-cell activation and the flexibility to encode multi-stage fusion antigens targeting both active and latent bacilli. However, significant constraints remain; mRNA technology alone cannot resolve the spatial sequestration of Mtb within necrotic granulomas or the "recruitment lag" of systemic immunity to the lung parenchyma. Achieving sterile protection requires a transition toward mucosal delivery systems capable of inducing lung T

Indexed as

Antigens, BacterialMycobacterium tuberculosisRNA, MessengerTuberculosisTuberculosis VaccinesVaccine DevelopmentAnimalsCD8-Positive T-LymphocytesHumansmRNA VaccinesVaccines, SyntheticAntigens, BacterialmRNA VaccinesRNA, MessengerTuberculosis VaccinesVaccines, SyntheticAntigen designImmunopathogenesisLung-resident memoryMessenger RNAMycobacterium tuberculosisPulmonary immunityTrained immunityVaccine delivery

Identifiers

PMID42084636

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.